Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. Co. is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. Co.'s ARCALYST is interleukin-1alpha (IL-1?), and interleukin-1beta (IL-1?), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. The KNSA average annual return since 2018 is shown above.
The Average Annual Return on the KNSA average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KNSA average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KNSA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free KNSA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
